Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction.

@article{Mir1998EmergenceOC,
  title={Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction.},
  author={Elisenda Mir{\'o} and Margarita Del Cuerpo and Ferr{\'a}n Navarro and Montserrat Sabat{\'e} and Beatriz Mirelis and Guillem Prats},
  journal={The Journal of antimicrobial chemotherapy},
  year={1998},
  volume={42 4},
  pages={535-8}
}
Between 1994 and 1996 we detected 28 out of 7054 (0.4%) clinical isolates of Escherichia coli with abnormal or reduced inhibition diameters to co-amoxiclav and ceftazidime in a disc diffusion test. The increased MIC of ceftazidime (1-32 mg/L) and the effect of synergy between this antibiotic and co-amoxiclav according to the disc diffusion test suggest the presence of an extended-spectrum beta-lactamase. However, enzymatic characterization and the nucleotide sequence confirm the hyperproduction… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

TEMand SHV-derived extended-spectrum -lactamases: relationship between selection, structure and function

  • S. K. Du Bois, M. S. Marriott, S. G. Amyes
  • Journal of Antimicrobial Chemotherapy
  • 1995
1 Excerpt

Une méthode simple de marquage épidémiologique: la biotypie, application à Enterobacter cloacae et Escherichia coli

  • C. Richard
  • Bulletin de l’Association des Anciens Élèves de…
  • 1981

Similar Papers

Loading similar papers…